Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : Tiumbio
Deal Size : Undisclosed
Deal Type : Private Placement
TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data
Details : The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.
Brand Name : TU2670
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 29, 2023
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Tiumbio
Deal Size : Undisclosed
Deal Type : Private Placement
Lead Product(s) : Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Regulatory Approval of COVID-19 Vaccine SKYCovion
Details : SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.
Brand Name : SKYCovion
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 26, 2023
Lead Product(s) : Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SARS-CoV-2 Surface Spike Protein,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EMA’s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine
Details : Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.
Brand Name : Skycovion
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 20, 2022
Lead Product(s) : SARS-CoV-2 Surface Spike Protein,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Standigm
Deal Size : Not Applicable
Deal Type : Not Applicable
Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate
Details : The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
January 07, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Standigm
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylbenzylamine
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : AriBio
Deal Size : Not Applicable
Deal Type : Not Applicable
AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
Details : AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.
Brand Name : AR1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2020
Lead Product(s) : Methylbenzylamine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : AriBio
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?